Why Pig Organs Could Be the Future of Transplants
Making human tissue in a lab has always been more sci-fi than sci-fact, but powerful genetic technologies may change that soon. For the most part, the only way to replace diseased or failing hearts, lungs, kidneys and livers is with donor organs. Even then, many people struggle to find a good biological match with a donor, and 8,000 die each year in the U.S. while waiting for an organ. In one promising solution to the shortage, researchers have been putting a new DNA editing tool called CRISPR through rigorous tests in organ regeneration. Last August, a group of scientists led by George Church, professor of genetics at Harvard Medical School, generated more than a dozen pigs that were bred without certain viruses that had made many of their organs unusable for human transplant. Pig genomes often contain genes for viruses that can cause infection and, if they spread to certain tissues, even cancer. Church used CRISPR to snip out these viral genes from the pig DNA. While there are other ways to edit DNA, CRISPR, developed in 2012, is by far the most precise set of molecular tools to cut, paste, copy and move genes around. In order to ensure that all the tissues in the pigs were free of the viruses, Church and his team used a cloning technique to create embryos from the edited cells. Of 37 pigs that were born, 15 survived, and none showed genetic signs of the viruses. Church anticipates that pig-to-human organ transplant clinical trials could happen in as little as two years, w...
Authors: Yang DH, Kim HJ, Park K, Kim JK, Chun HJ Abstract Poly-l-lysine (PLL) nanoparticle (NP) system was prepared for the controlled release of curcumin (CUR) by pH stimuli, and its theranostic efficacy on cancer was compared to that of CUR solution in vitro and in vivo. Deoxycholic acid (DOCA), methoxy polyethylene glycol (MPEG) and cyanine 5.5 (cy5.5) were conjugated to the amine group of PLL through condensation reaction (PLL-DOCA-MPEG-cy5.5), followed by encapsulation of CUR by dialysis method (PLL-DOCA-MPEG-cy5.5/CUR NPs). The composition, morphology and size distribution of PLL-DOCA-MPEG-cy5.5 NPs were cha...
CONCLUSIONS: Downregulation of miR-340 inhibited GC cell proliferation, arrested cell cycle, and facilitated apoptosis through upregulating SOCS3 expression to suppress JAK-STAT3 signaling pathway. PMID: 29658372 [PubMed - as supplied by publisher]
The medical garment developed at the McGill University Health Centre addresses a little-discussed problem that arises when women with larger breasts go in for radiation treatment.
AbstractIn the original version of this article, there is a typo in the family name of the author. The co-author family name should be Seyed Bagheri; instead, it has been published as Seyed bagheri.
Peng Ye, Yu Shi, Anling Li
New J. Chem., 2018, Accepted Manuscript DOI: 10.1039/C8NJ00814K, PaperPriyankar Paira, Bharthi MV, Sourav De, Lavanya Thilak Babu, Santanu Maiti, Bidisha Sarkar, Ashok S.K. Kumar Abstract: Surface immobilization of DNA conjugates via SPAAC for cancer theranostic application reported here. The formation of DNA conjugates was supported by absorption and emission studies. The luminescent DNA conjugates... The content of this RSS Feed (c) The Royal Society of Chemistry
AbstractNeomycin is known to preferentially bind to A-form nucleic acid structures including triplex DNA, DNA and RNA hybrid, and duplex RNA. Tethering a DNA intercalator moiety to the C5 ” position of the ring III of neomycin is a practical approach to develop potent binders targeting various nucleic acid secondary structures via a synergistic effect; however, the minimal stacking surface of the intercalating moiety required to exhibit the effect remains unclear. In the present wo rk, we synthesized four nucleobase and neomycin conjugates via click chemistry. All four conjugates stabilized a DNA oligonucleotide trip...
Boston Scientific Corp. said Monday that it has bought nVision Medical Corp., a med-tech firm founded by a Harker School graduate that's developing a device to screen women for ovarian cancer. The Star Tribune of Minneapolis reported that Massachusetts-based Boston Scientific (NYSE: BSX) will pay $150 million upfront and another $125 million in later payments to acquire San Bruno-based nVision. RELATED: Read Boston Scientific's full announcement NVision had raised only about $17 mill ion in funding…
Jerome Hamon has been dubbed the "man with three faces"
The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer.
More News: Burns | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Genetics | Harvard | Health | Heart | Heart Transplant | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Lung Transplant | Medical Ethics | Molecular Biology | Pancreas | Pancreatic Cancer | Skin | Skin Graft | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Urology & Nephrology